Meeting
2023 ASCO Gastrointestinal Cancers Symposium
A meta-analysis of bevacizumab’s cardiovascular risks in patients treated for colorectal cancer.
Authors
Akshit Chitkara
University of California Riverside, Riverside, CA;
Akshit Chitkara , Aditya Desai , Devanshi Mehta , Nirmaljot Kaur , Fnu Anamika , Darshi Desai , Rajat Thawani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 113)
DOI
10.1200/JCO.2023.41.4_suppl.113
Abstract #
113
Poster Bd #
F10
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Olaparib ± bevacizumab versus bevacizumab + fluorouracil in patients with unresectable or metastatic colorectal cancer not progressing on first-line FOLFOX + bevacizumab: Phase III LYNK-003 study.
First Author: Carlos Alberto Mayo
Poster
2017 Gastrointestinal Cancers Symposium
Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial.
First Author: Wenjing Wang
Poster
2015 Gastrointestinal Cancers Symposium
Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2—Results of the induction phase of the GERCOR DREAM randomized phase III study.
First Author: Christophe Tournigand
Poster
2014 Gastrointestinal Cancers Symposium
The importance of sequence in rescheduling bevacizumab and chemotherapy administration in the first-line treatment of metastatic colorectal carcinoma (mCRC).
First Author: Leonidas Chelis